Login to Your Account



Antisense Comes of Age as Kynamro NDA in FDA Queue

By Marie Powers
Staff Writer

Wednesday, May 30, 2012

The use of antisense oligonucleotides in biotech drug development took another step forward with the FDA's acceptance of the new drug application (NDA) for Kynamro (mipomersen sodium) filed by Genzyme, a unit of Sanofi SA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription